#Merck Provides Update on #KEYNOTE361 trial #KEYTRUDA with #Chemotherapy for the first-line treatment of advanced or metastatic #UrothelialCarcinoma did not meet its pre-specified dual primary endpoints of overall survival or progression-free survival $MRK https://t.co/sMSQBJ6qWT